Phase I Multiple Ascending Dose Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of BMS-582664 in Japanese Patients With Advanced or Metastatic Solid Tumors.
Latest Information Update: 12 Jan 2011
At a glance
- Drugs Brivanib alaninate (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 29 Jun 2010 Actual patient number (13) added as reported by ClinicalTrials.gov.
- 06 Apr 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
- 06 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.